Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Zutphen – page 7

842 clinical trials in Zutphen, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Zutphen at a glance
842
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

842 trials in Zutphen

Open in trial search

Low‑dose human serum albumin versus standard dose during large‑volume paracentesis in patients with liver cirrhosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Human Serum Albumin
  • Sponsor:Amsterdam UMC Stichting

A Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:MK-8690
  • Sponsor:Merck Sharp & Dohme LLC

Long‑Term Safety and Efficacy Study of ENTR‑601‑45 and ENTR‑601‑44 in Participants with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:ENTR-601-44
  • Sponsor:Entrada Therapeutics Inc.

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Merck Sharp & Dohme LLC

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Discontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Sint Maartenskliniek

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Verastem Inc.

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Zutphen

What the registry says about research in the country

01 Respiratory Diseases

Clinical research focusing on respiratory conditions including innovative treatments for asthma and viral infections. Studies encompass evaluation of new vaccine combinations and safety assessments of inhalation devices.

  • RSV and COVID-19 vaccine co-administration
  • Moderate to severe asthma treatments
  • Chronic Obstructive Pulmonary Disease management
  • Bronchiectasis therapy

Investigations include both preventive measures and therapeutic interventions for respiratory conditions.

02 Cardiovascular Studies

Comprehensive research into cardiovascular health, examining treatments for various heart conditions and prevention of major cardiac events.

  • Atherosclerotic Cardiovascular Disease
  • Heart Failure Management
  • Post-Heart Attack Treatment
  • Acute Coronary Syndrome

Focus on innovative therapies and interventions to improve patient outcomes in heart-related conditions.

03 Oncology Research

Advanced studies in lung cancer treatment and innovative therapeutic approaches for various cancer types.

  • Non-Small Cell Lung Cancer therapies
  • Immunotherapy optimization
  • Mantle Cell Lymphoma treatment

Evaluating novel treatment combinations and immunotherapy approaches for better patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.